Drugs / Voluven
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00633659 | Sep 2007 → Jun 2008 | limb ischemia | Sangart | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT02113358 | Apr 2014 → May 2015 | primary brain neoplasm, supratentorial cancer | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT01729364 | Apr 2008 → Dec 2014 | impaired renal function disease | Sahlgrenska University Hospital | Completed | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 0 | NCT03465943 Comparator | Mar 2018 → Mar 2019 | hypotensive disorder | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01087853 Comparator | Mar 2010 → Mar 2011 | disorder of acid-base balance, water intoxication | University of Nottingham | Completed | No outcome recorded |
| Phase 2 | NCT00317512 Comparator | Dec 2003 → Apr 2005 | intermediate coronary syndrome, myocardial infarction | Biopure Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00444262 Comparator | Apr 2007 → Nov 2010 | bone disorder | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00420277 Comparator | Feb 2007 → Mar 2008 | hypotensive disorder, ischemic disease | Sangart | Completed | Met primary |
| Phase 3 | NCT00421200 Comparator | Feb 2007 → May 2008 | hypotensive disorder, ischemic disease | Sangart | Completed | Met primary |
| — | NCT03249298 Comparator | Jan → Dec 2017 | — | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT02570724 Comparator | Jun 2013 → Aug 2018 | intracranial hypotension | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| — | NCT01512628 Comparator | Jan 2012 → Dec 2013 | avascular necrosis | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT01819571 Background | Jan 2012 → Oct 2013 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01452581 Comparator | Oct 2011 → Sep 2012 | osteoarthritis, hip | Rigshospitalet, Denmark | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01972828 Background | Jul 2007 → Aug 2013 | infectious disease with sepsis | Hospices Civils de Lyon | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Voluven | “Goals : Primary endpoint is to demonstrate that colloid (Voluven®) titration, guided using esophageal Doppler estimation of stroke volume, during the surgical repair of hip...” NCT00444262 ↗16“In Phase B, 12 subjects will receive 1 litre of PlasmaVolume® (Baxter Health Care, Thetford, UK) or Voluven® (Fresenius Kabi, Bad Homburg, Germany).” NCT01087853 ↗ “Voluven” NCT03249298 ↗ “Voluven” NCT01729364 ↗ |
| Known as | HES 130/0.4 | “HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups” NCT01819571 ↗2“hydroxyethyl starch (HES) solution (Voluven®; HES 130/0.4)” PMID 21317165 ↗ Feb 2011 “Voluven (HES 130/0.4)” NCT00421200 ↗ |
| Modality | Other / unclassified | “colloid (Voluven®)” NCT00444262 ↗ |
| Route | Intravenous | “Intravenous colloid bolus with Voluven” NCT02113358 ↗ |